Skip to main content

Table 6 Multivariate analysis of patient baseline characteristics for the effect of interaction with axitinib titration on OS

From: Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study

Parameter

HR for Covariate

Placebo Titration

Axitinib Titration

Metastatic site (≥3 vs. ≤2)

2.191

4.438

Time from histopathological diagnosis to treatment (< 1 vs. ≥1 year)

1.437

3.569

Baseline Hb < LLN (yes vs. no)

0.940

3.378

  1. Abbreviations: CI confidence interval, Hb haemoglobin, HR hazard ratio, LLN lower limit of normal